E3 ligases conjugate ubiquitin to specific target proteins, signaling changes such as directing them to the proteasome for degradation. DUBs cleave ubiquitin from target proteins, including other ubiquitins. Ubiquitin conjugation and deconjugation both have physiological consequences and can be manipulated by small molecules for therapeutic effect.
Since 2002 Progenra scientists have been working to understand the intricacies of the ubiquitin pathway to maximize discovery of new classes of molecules. This work has led to the creation of a comprehensive toolbox termed the UbiPro™ Drug Discovery Platform for studying DUBs and E3 Ligases which we use to screen our diverse collection of >320,000 drug-like small molecules.
There are three components to the UbiPro™ platform: